On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013;En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificación del posicionamiento terapéutico UT/V4/23122013

Revista Espanola de Cardiologia

Volumn 69, Issue 6, 2016, Pages 551-553

  Roldán, Inmaculada ^a   Marín, Francisco ^b   Tello Montoliu, Antonio ^c   Roldán, Vanessa ^c   Anguita, Manuel ^c   Ruiz Nodar, Juan Miguel ^c   Íñiguez, Andrés ^c   González Juanatey, José Ramón ^c   Rodríguez Padial, Luis ^c   Badimón, Lina ^c   Mateo, José ^c   Vicente, Vicente ^c   Gallego Culleré, Jaime ^c   Masjuan, Jaime ^c   González Armengol, Juan J ^c   Marín Martínez, Alfonso ^c   Coll Vinent, Blanca I Puig ^c   Casariego Vales, Emilio ^c   Llisterri Caro, José Luis ^c   Polo García, José ^c   Rodríguez Roca, Gustavo C ^c   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ATRIAL FIBRILLATION; NONVALVULAR ATRIAL FIBRILLATION; REVIEW; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; HUMAN; RISK ASSESSMENT; SPAIN; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; RISK ASSESSMENT; SPAIN; STROKE; WARFARIN;

EID: 85016924445     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2016.03.004     Document Type: Article

References (17)

1. A.J. Camm, G.Y. Lip, R. de Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, et al. Developed with the special contribution of the European Heart Rhythm Association 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Eur Hear J. 33 2012 2719 2747
2. A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb Haemost. 106 2011 968 977
3. M. Anguita Sánchez, V. Bertomeu Martínez, A. Cequier Fillat en representación de los investigadores del estudio CALIFA Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados Rev Esp Cardiol. 68 2015 761 768
4. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials Lancet. 383 2014 955 962
5. Agencia Española de Medicamentos y Productos Sanitarios. Criterios y recomendaciones para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular [citado 9 Mar 2016]. Disponible en: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/home.htm#anticoagulantes-orales.
6. Roldán I, Marín F, Tello-Montoliu A, Roldán V, Anguita M, Ruiz-Nodar JM, et al. Propuesta de modificación de posicionamiento terapéutico para uso de NACO [citado 5 Mar 2016]. Disponible en: http://secardiologia.es/institucional/comunicados/comunicados-oficiales/6541-propuesta-de-modificacion-de-posicionamiento-terapeutico-para-uso-de-naco.
7. 2 score 0-1: a nationwide cohort study Thromb Haemost. 107 2012 1172 1179
8. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.E. Cigarroa, J.C. Cleveland Jr., and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society Circulation. 130 2014 e199 e267
9. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
10. R. Pisters, R. Nieuwlaat, D.A. Lane, H.J. Crijns, and G.Y. Lip Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey Thromb Haemost. 109 2013 328 336
11. National Institute for Health and Care Excellence (NICE) Atrial fibrillation: the management of atrial fibrillation. Clinical Guideline Methods, evidence and recommendations June 2014 National Clinical Guideline Centre [citado 5 Mar 2016]. Disponible en: http://www.nice.org.uk/guidance/cg180/evidence.
12. D.A. Garcia, R.D. Lopes, and E.M. Hylek New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs Thromb Haemost 104 2010 1099 1105
13. P. Gallego, V. Roldan, F. Marín, M. Romera, M. Valdés, V. Vicente, and et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost. 110 2013 1189 1198
14. 2 score predicts poor anticoagulation in atrial fibrillation patients initiating vitamin K antagonists: A prospective "real world" inception cohort study Am J Med. 128 2015 1237 1243
15. A.J. Rose, D.R. Berlowitz, A.S. Ash, A. Ozonoff, E.M. Hylek, and J.D. Goldhaber-Fiebert The business case for quality improvement: oral anticoagulation for atrial fibrillation Circ Cardiovasc Qual Outcomes. 4 2011 416 424
16. R. Cappato, M.D. Ezekowitz, A.L. Klein, A.J. Camm, C.S. Ma, J.Y. Le Heuzey, and et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur Heart J. 35 2014 3346 3355
17. E. Santas, J. Méndez, A. Martínez-Brotons, J. Núñez, F.J. Chorro, and R. Ruiz-Granell Experiencia en la práctica clínica diaria con la cardioversión ambulatoria de fibrilación auricular en tratamiento con nuevos anticoagulantes orales Rev Esp Cardiol. 67 2014 960 961